ArticleJournal of thoracic disease2026
Research progress and trends on DNA methylation research in non-small cell lung cancer: a bibliometric analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: DNA methylation plays a key role in non-small cell lung cancer (NSCLC) pathogenesis. This study aimed to explore the global research landscape and frontier trends of DNA methylation and NSCLC through bibliometric analysis. Methods: A literature search was conducted in the Web of Science Core Collection (WoSCC), focusing on articles published from January 2008 to April 2025. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package "bibliometrix" to visualize collaborations, keyword co-occurrences, and emerging research trends. Results: The analysis identified 573 articles authored by 4,356 researchers across 2,524 institutions in 174 countries. China (n=288), the USA (n=77), and South Korea (n=33) were the countries with the highest number of published articles, with Nanjing Medical University in China (n=74) emerging as the leading institution. Clinical Cancer Research had the highest total link strength in co-occurrence networks. High-impact authors included Esteller Manel and Herman James G. Keyword clustering identified seven major themes: Hypermethylation in NSCLC, DNA methylation in therapy against NSCLC, DNA methyltransferases (DNMTs) in NSCLC, DNA methylation as a biomarker in early diagnosis for NSCLC, single nucleotide polymorphisms (SNPs) in NSCLC, cigarette smoke-related abnormal DNA methylation, and DNA methylation in other cancers. Notably, since 2022, the emergence of "activation" and "transcription" continued through to 2025. Conclusions: This bibliometric analysis highlights the important role of DNA methylation in NSCLC. Moving forward, research efforts should focus on elucidating the specific molecular mechanisms within the broader epigenetic network of NSCLC, rather than studying DNA methylation in isolation. Such an approach may enhance the efficacy of therapies targeting epigenetic regulators and modifiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.